

References

- . **AFFIRM** -The Atrial Fibrillation Follow Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002;347:1825-1833.
- . **Agarwal AK, Venugopalan P.** Left atrial spontaneous echo contrast in patients with rheumatic mitral valve stenosis in sinus rhythm: relationship to mitral valve and left atrial measurements. *Int J Cardiol.* 2001; 77: 63–8.
- . **Agmon Y, Khandheria BK, Gentile F, et al.** Echocardiographic assessment of the left atrial appendage. *J Am Coll Cardiol.* 1999; 34: 1867–77.
- . **Aime-Sempe C, Folliguet T, Rucker-Martin C, et al.** Myocardial cell death in fibrillating and dilated human right atria. *J Am Coll Cardiol.* 1999; 34: 1577–86.
- . **Akyurek O, Sayin T, Dincer I, et al.** Lengthening of intraatrial conduction time in atrial fibrillation and its relation with early recurrence of atrial fibrillation. *Jpn Heart J.* 2001; 42: 575–84.
- . **Albers GW, Diener HC, Frison L, et al.** Ximelagatran vs. warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. *JAMA.* 2005; 293: 690–8.
- . **Albers GW-, Kemp S, Hall EAlbers GW, et al .** Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. *Arch Intern Med.* 1996 Nov 11; 156(20):2311-6. Stanford University Medical Center, Palo Alto, CA, USA.
- . **Albers G.W, Dalen J.E., Laupacis A., et al.** Antithrombotic therapy in atrial fibrillation. *Chest* 119 Suppl (2001), pp. 194S–206S.
- . **Alboni P, Botto GL, Baldi N, et al.** Outpatient treatment of recent onset atrial fibrillation with the âœpill in the pocket-approach. *N Engl J Med* 2004;351:2384-2391.
- . **Allessie M, Ausma J, Schotten U.** Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res.* 2002; 54: 230–46.

References

- . **Allessie MA, Konings KT, Kirchhof CJ.** Mapping of atrial fibrillation. In: Olsson SB, Allessie MA, Campbell RW, editors. *Atrial Fibrillation: Mechanisms and Therapeutic Strategies*. Armonk, NY: Futura, 1994: 37–49.
- . **Anand SS, Yusuf S.** Oral anticoagulant therapy in patients with coronary artery disease: a meta-analysis. *JAMA* 1999;282:2058–67.
- . **Anderson DR, Gardner MJ, Putnam W, et al.** Population-based evaluation of the management of antithrombotic therapy for atrial fibrillation, *Can J Cardiol*. 2005 Mar; 21(3):257-66.
- . **Anderson S, Blanski L, Byrd RC, et al.** Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias: the Esmolol vs. Placebo Multicenter Study Group. *Am Heart J* 1986;111:42-48.
- . **Ang SY, Peterson GM, Friesen WT, et al.** Review of antithrombotic drug usage in atrial fibrillation. *J Clin Pharm Ther*. 1998 Apr;23(2):97-106.
- . **Anne W, Willems R, Van der MN, et al.** Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics. *Heart*. 2004; 90: 1025–30.
- . **Aschenberg W, Schluter M, Kremer P, et al.** Transesophageal two-dimensional echocardiography for the detection of left atrial appendage thrombus. *J Am Coll Cardiol*. 1986; 7: 163–6.
- . **Bailey GW, Braniff BA, Hancock EW, et al.** Relation of left atrial pathology to atrial fibrillation in mitral valvular disease. *Ann Intern Med*. 1968; 69: 13–20.
- . **Baker WL, Cios DA, Sander SD, et al.** Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States. *J Manag Care Pharm*. 2009 Apr; 15(3):244-52.
- . **Barbara S, Zehnder1, Beat A, et al.** Stefan Osswald. Atrial fibrillation: Estimated increased rate of stroke due to lacking adherence to guidelines *SWISS MED WKLY* 2006; 136: 757-760.
- . **Bellet S.** *Clinical Disorders of the Heart Beat*. 3rd ed. Philadelphia: Lea & Febiger, 1971.

References

- . **Benavente O, Hart RG.** Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy in atrial fibrillation. *J Neurol Sci* 1997; 153:110.
- . **Berger M, Schweitzer P.** Timing of thromboembolic events after electrical cardioversion of atrial fibrillation or flutter: a retrospective analysis. *Am J Cardiol.* 1998; 82: 1545–7, A8.
- . **Berwaerts J, Webster J.** Analysis of risk factors involved in oral anticoagulant-related intracranial haemorrhages. *QJM* 2000;93:513–21.
- . **Beyth RJ, Quinn L, Landefeld CS.** A multicomponent intervention to prevent major bleeding complications in older patients receiving warfarin. A randomized, controlled trial. *Ann Intern Med* 2000;133: 687–95.
- . **Bharti S, Lev M.** Histology of the normal and diseased atrium. In: Fall RH, Podrid PJ, editors. *Atrial Fibrillation: Mechanism and Management*. New York: Raven Press, 1992: 15–39.
- . **Bianconi L, Boccadamo R, Pappalardo A, et al.** Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. *Am J Cardiol* 1989;64:335–338.
- . **Biblo LA, Yuan Z, Quan KJ, et al.** Risk of stroke in patients with atrial flutter. *Am J Cardiol.* 2001; 87: 346–9, A9.
- . **Birman-Deych E, Radford MJ, Nilasena DS, et al.** Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. *Stroke* 2006;37:1070–1074.
- . **Bjerkelund, CJ, Orning, OM** The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. *Am J Cardiol* 1969;23:208–216
- . **Blackshear JL, Johnson WD, Odell JA, et al.** Thoracoscopic extracardiac obliteration of the left atrial appendage for stroke risk reduction in atrial fibrillation. *J Am Coll Cardiol* 2003;42:1249–52.
- . **Botto GL, Bonini W, Broffoni T, et al.** Conversion of recent onset atrial fibrillation with single loading oral dose of propafenone: is in-hospital admission absolutely necessary? *Pacing Clin Electrophysiol* 1996;19:1939–1943.

References

- . **Boysen G, Nyboe J, Appleyard M, et al.** Stroke incidence and risk factors for stroke in Copenhagen, Denmark. *Stroke* 1988;19:1345–53.
- . **Bradley D, Creswell LL, Hogue CW, et al.** ACCP Guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. *Pharmacological prophylaxis. Chest* 2005;128:395–475.
- . **Brand FN, Abbott RD, Kannel WB, et al.** Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. *JAMA*. 1985; 254: 3449–53
- . **Brookes CI, White PA, Staples M, et al.** Myocardial contractility is not constant during spontaneous atrial fibrillation in patients. *Circulation*. 1998; 98: 1762–8.
- . **Brouwer MA, van den Bergh PJ, Aengevaeren WR, et al.** Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: results of the Antithrombotics in the Prevention of Reocclusion In Coronary Thrombolysis (APRICOT)-2 Trial. *Circulation* 2002;106:659–65.
- . **Brugada R, Tapscott T, Czernuszewicz GZ, et al.** Identification of a genetic locus for familial atrial fibrillation. *N Engl J Med*. 1997; 336: 905–11.
- . **Bungard, Pharm D, Margaret L, et al.** Adequacy of Anticoagulation in patients with Atrial Fibrillation Coming to Hospital. *Pharmacotherapy* 2000; 20 (9): 1060-1065.
- . **Bungard TJ, Ghali WA, Teo KK, et al.** Why do patients with atrial fibrillation not receive warfarin? *Arch Intern Med* 2000; 160: 41-6.
- . **Cappato, R, Calkins, H, Chen, SA, et al** .Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. *Circulation* 2005;111,1100-1105
- . **Chimowitz MI, DeGeorgia MA, Poole RM, et al.** Left atrial spontaneous echo contrast is highly associated with previous stroke in patients with atrial fibrillation or mitral stenosis. *Stroke*. 1993; 24: 1015–9.
- . **Chen SA, Tai CT, Yu WC, et al.** Right atrial focal atrial fibrillation: electrophysiologic characteristics and radiofrequency catheter ablation. *J Cardiovasc Electrophysiol*. 1999; 10: 328–35.

References

- . **Collins LJ, Silverman DI, Douglas PS, et al.** Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. *Circulation*. 1995; 92: 160–3.
- . **Connolly SJ, Ezekowitz MD, Yusuf S, et al.** Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139-1151.
- . **Connolly SJ, Laupacis A, Gent M, et al.** Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol* 1991;18:349 –55.
- . **Connolly SJ, Pogue J, Eikelboom J, et al.** Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circulation* 2008;118:2029-2037.
- . **Connolly ST, et al.** Atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE). Late breaking clinical report presented at the Scientific Sessions 2005 of the American Heart Association, Dallas, TX; 2006.
- . **Connolly, S, Pogue, J, Hart, R, et al .** Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. *Lancet* 2006;367,1903-1912
- . **Corrado, G, Tadeo, G, Beretta, S, et al** Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. *Chest* 1999;115,140-143
- . **Corrado, G, Beretta, S, Sormani, L, et al .** Prevalence of atrial thrombi in patients with atrial fibrillation/flutter and subtherapeutic anticoagulation prior to cardioversion. *Eur J Echocardiogr* 2004;5,257-261
- . **Coumadin Aspirin Reinfarction Study (CARS) Investigators.** Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. *Lancet* 1997;350:389 –96.
- . **Coumel P.** Neural aspects of paroxysmal atrial fibrillation. In: Falk RH, Podrid PJ, editors. *Atrial Fibrillation: Mechanisms and Management*. New York: Raven Press, 1992: 109–25.

References

- . **Cox JL, Canavan TE, Schuessler RB, et al.** The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiology mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation. *J Thorac Cardiovasc Surg* 1991;101:406-426.
- . **Crijns HJ, Tjeerdsma G, De Kam PJ, et al.** Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. *Eur Heart J*. 2000; 21: 1238-45.
- . **Crystal E, Lamy A, Connolly SJ, et al.** Left Atrial Appendage Occlusion Study (LAAOS): a randomized clinical trial of left atrial appendage occlusion during routine coronary artery bypass graft surgery for long-term stroke prevention. *Am Heart J* 2003;145:174-8.
- . **Darbar D, Herron KJ, Ballew JD, et al.** Familial atrial fibrillation is a genetically heterogeneous disorder. *J Am Coll Cardiol*. 2003; 41: 2185-92
- . **Dunn MI, Marcum JL.** Atrial mechanical performance following internal and external cardioversion of atrial fibrillation: its relationship to peripheral embolization and acute cerebrovascular accident. *Chest*. 2002; 121: 1-3.
- . **EAFT** (European Atrial Fibrillation Trial) Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet* 1993;342:1255- 62.
- . **Ellinor PT, Shin JT, Moore RK, et al.** Locus for atrial fibrillation maps to chromosome 6q14-16. *Circulation*. 2003; 107: 2880-3.
- . **Epstein AE, Alexander JC, Gutterman DD, et al.** American College of Chest Physicians guidelines for the prevention and management of postoperative atrial fibrillation after cardiac surgery. *Chest* 2005;128:245-275.
- . **European Stroke Prevention Study.** ESPS Group. *Stroke*. 1990; 21: 1122-30.
- . **Ezekowitz MD, Bridgers SL, James KE, et al.** Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators [published erratum appears in *N Engl J Med* 1993; 328(2):148]. *N Engl J Med* 1992;327:1406-12.

References

- . **Ezekowitz MD, Connolly SJ, Parekh A, et al.** Rationale and design of RELY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. *Am Heart J* 2009;157:805-810.
- . **Fang MC, Chang Y, Hylek EM, et al.** Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. *Ann Intern Med.* 2004; 141: 745–52.
- . **Fang MC, Singer DE, Chang Y, et al.** Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation.* 2005; 112: 1687–91.
- . **Faniel R, Schoenfeld PH.** Efficacy of i.v. amiodarone in converting rapid atrial fibrillation and flutter to sinus rhythm in intensive care patients. *Eur Heart J* 1983;4:180-185.
- . **Fatkin D, Kelly RP, Feneley MP.** Relations between left atrial appendage blood flow velocity, spontaneous echocardiographic contrast and thromboembolic risk in vivo. *J Am Coll Cardiol.* 1994; 23: 961–9.
- . **Fatkin D, Kuchar DL, Thorburn CW, et al.** Transesophageal echocardiography before and during direct current cardioversion of atrial fibrillation: evidence for “atrial stunning” as a mechanism of thromboembolic complications. *J Am Coll Cardiol* 1994;23:307–16.
- . **Friberg J, Buch P, Scharling H, Gadsbphioll N, et al.** Rising rates of hospital admissions for atrial fibrillation. *Epidemiology.* 2003; 14: 666–72.
- . **Feinberg WM, Kronmal RA, Newman AB, et al.** Stroke risk in an elderly population with atrial fibrillation. *J Gen Intern Med.* 1999; 14: 56–9.
- . **Fenster PE, Comess KA, Marsh R, et al.** Conversion of atrial fibrillation to sinus rhythm by acute intravenous procainamide infusion. *Am Heart J* 1983;106:501-504.
- . **Fioranelli M, Piccoli M, Mileto GM, et al.** Analysis of heart rate variability five minutes before the onset of paroxysmal atrial fibrillation. *Pacing Clin Electrophysiol.* 1999; 22: 743–9.
- . **Fiore LD, Ezekowitz MD, Brophy MT, et al.** Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial

infarction: primary results of the CHAMP study. *Circulation*. 2002; 105: 557–63.

. **Flaker, GC, Gruber, M, Connolly, SJ, et al** .Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. *Am Heart J* 2006.

. **Fox CS, Parise H, D’Agostino RB Sr, et al**. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. *JAMA*. 2004; 291: 2851–5.

. **Friberg J, Scharling H, Gadsboll N, et al**. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). *Am J Cardiol*. 2003; 92: 1419–23.

. **Frost L, Hune LJ, Vestergaard P**. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. *Am J Med*. 2005; 118: 489–95.

. **Frykman V, Beerman B, Ryden L, et al**. Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. *Eur Heart J* 2001; 22:1954 –9.

. **Fuster V, Ryden LE, Asinger RW, et al**. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. *Eur Heart J* 2001;22: 1852–923.

. **Fuster V, Rydén LE, Cannom DS, et al**. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006;114:e257-e354. [Erratum, *Circulation* 2007;116(6):e138.

References

- . **Gage BF, van Walraven C, Pearce L, et al.** Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. *Circulation* 2004;110:2287–92.
- . **Gage BF, Waterman AD, Shannon W, et al.** Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA* 2001;285:2864 –70.
- . **Gallagher MM, Camm J.** Classification of atrial fibrillation. *Am J Cardiol.* 1998; 82: 18N–28N.
- . **Gallagher JJ, Svenson RH, Kasell JH, et al.** Catheter technique for closed-chest ablation of the atrioventricular conduction system: a therapeutic alternative for the treatment of refractory supraventricular tachycardia. *N Engl J Med* 1982;306:194-200.
- . **Gallagher, MM, Hennessy, BJ, Edvardsson, N.** Embolic complications of direct current cardioversion of atrial arrhythmias: association with low intensity of anticoagulation at the time of cardioversion. *J Am Coll Cardiol* 2002;40,926-933
- . **Galve E, Rius T, Ballester R, et al.** Intravenous amiodarone in treatment of recent-onset atrial fibrillation: results of a randomized, controlled study. *J Am Coll Cardiol* 1996;27:1079-1082.
- . **Gibson CM, Mega JL, Hammett CJ, et al.** Randomized comparison of rivaroxaban, an oral direct factor xa inhibitor, with placebo in patients with acute coronary syndromes: the ATLAS ACS-TIMI 46 Trial. *Circulation.* 2008;118:2311.
- . **Glazer NL, Dublin S, Smith NL, et al.** Newly detected atrial fibrillation and compliance with antithrombotic guidelines. *Arch Intern Med.* 2007 Feb 12; 167(3):246-52. Cardiovascular Health Research Unit and Department of Epidemiology, University of Washington, 1730 Minor Avenue, Seattle, WA 98101, USA.
- . **Go AS, Hylek EM, Borowsky LH, et al.** Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. *Ann Intern Med.* 1999 Dec 21;131(12):927-34.

References

- . **Go AS, Hylek EM, Chang Y, et al.** Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? *JAMA*. 2003; 290: 2685–92.
- . **Go AS, Hylek EM, Phillips KA, et al.** Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. *Circulation*. 2000; 102: 11–3.
- . **Go AS, Hylek EM, Phillips KA, et al.** Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001; 285: 2370–5.
- . **Go AS, Reed GL, Hylek EM, et al.** Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *J Thromb Thrombolysis*. 2003; 15: 41–6.
- . **Goette A, Arndt M, Rocken C, et al.** Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. *Circulation*. 2000; 101: 2678–81.
- . **Goette A, Staack T, Rocken C, et al.** Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. *J Am Coll Cardiol*. 2000; 35: 1669–77.
- . **Goldberg RJ, Yarzebski J, Lessard D, et al.** Recent trends in the incidence rates of and death rates from atrial fibrillation complicating initial acute myocardial infarction: a community-wide perspective. *Am Heart J*. 2002; 143: 519–27.
- . **Goldman, M.** The management of chronic atrial fibrillation: indications and method of conversion to sinus rhythm. *Prog Cardiovasc Dis* 1959;2,465–479
- . **Gorter JW.** Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups. *Neurology*. 1999; 53: 1319–27.

References

- . **Gosselink AT, Crijns HJ, Hamer HP, et al.** Changes in left and right atrial size after cardioversion of atrial fibrillation: role of mitral valve disease. *J Am Coll Cardiol.* 1993; 22: 1666–72.
- . **Gosselink AT, Crijns HJ, VanGelder IC, et al.** Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. *JAMA* 1992;267:3289-3293.
- . **Guarnieri T, Tomaselli G, Griffith LSC, et al.** The interaction of antiarrhythmic drugs and the energy for cardioversion of chronic atrial fibrillation. *Pacing Clin Electrophysiol* 1991;14:1007-1012.
- . **Gullov AL, Koefoed BG, Petersen P.** Bleeding during warfarin and aspirin therapy in patients with atrial fibrillation: the AFASAK 2 study. Atrial Fibrillation Aspirin and Anticoagulation. *Arch Intern Med.* 1999; 159: 1322–8.
- . **Gurewich V.** Ximelagatran—promises and concerns. *JAMA* 2005;293: 736–9.
- . **Haissaguerre M, Jais P, Shah DC, et al.** Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. *N Engl J Med* 1998;339:659-666.
- . **Halperin JL, Gomberg-Maitland M.** Obliteration of the left atrial appendage for prevention of thromboembolism. *J Am Coll Cardiol* 2003;42:1259–61.
- . **Halperin JL, Hart RG.** Atrial fibrillation and stroke: new ideas, persisting dilemmas. *Stroke.* 1988; 19: 937–41.
- . **Halperin JL.** *Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation:* Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). *Am Heart J.* 2003; 146: 431–8.
- . **Halperin JL.** *Ximelagatran:* oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation. *J Am Coll Cardiol* 2005;45:1–9.
- . **Halpern SW, Ellrodt G, Singh BN, et al.** Efficacy of intravenous procainamide infusion in converting atrial fibrillation to sinus rhythm: relation to left atrial size. *Br Heart J* 1980;44:589-595.

References

- . **Hamer ME, Blumenthal JA, McCarthy EA, et al.** Quality-of-life assessment in patients with paroxysmal atrial fibrillation or paroxysmal supraventricular tachycardia. *Am J Cardiol.* 1994; 74: 826–9.
- . **Hart RG, Benavente O, McBride R, et al.** Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med.* 1999; 131: 492–501.
- . **Hart RG, Benavente O, Pearce LA.** Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. *Cerebrovasc Dis* 1999;9:215–7.
- . **Hart RG, Halperin JL.** Atrial fibrillation and stroke: concepts and controversies. *Stroke.* 2001; 32: 803–8.
- . **Hart RG, Halperin JL.** Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. *Ann Intern Med.* 1999; 131: 688–95.
- . **Hart RG, Pearce LA, Koudstaal PJ.** Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. *Stroke* 2004;35:948 –51.
- . **Hart RG, Pearce LA, McBride R, et al.** Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. *Stroke.* 1999; 30: 1223–9.
- . **Hart RG, Pearce LA, Miller VT, et al.** Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. *Cerebrovasc Dis.* 2000; 10: 39–43.
- . **Hart RG, Pearce LA, Rothbart RM, et al.** Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol.* 2000; 35: 183–7.
- . **Hart RG, Tonarelli SB, Pearce LA.** Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. *Stroke* 2005;36:1588 –93.

References

- . **Hartel G, Louhija A, Konttinen A.** Disopyramide in the prevention of recurrence of atrial fibrillation after electroconversion. *Clin Pharmacol Ther* 1974;15:551-555.
- . **Healey JS, Baranchuk A, Crystal E, et al.** Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. *J Am Coll Cardiol*. 2005; 45: 1832–9.
- . **Hellemons BS, Langenberg M, Lodder J, et al.** Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. *BMJ*. 1999; 319: 958–64.
- . **Henry WL, Morganroth J, Pearlman AS, et al.** Relation between echocardiographically determined left atrial size and atrial fibrillation. *Circulation* 1976;53:273-279.
- . **Higashikawa M, Nakamura Y, Yoshida M, et al.** Incidence of ischemic strokes in hypertrophic cardiomyopathy is markedly increased if complicated by atrial fibrillation. *Jpn Circ J* 1997;61:673– 81.
- . **Hilleman DE, Spinler SA.** Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials. *Pharmacotherapy* 2002;22:66-74.
- . **Hindricks, G, Piorkowski, C, Tanner, H, et al.** Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. *Circulation* 2005;112,307-313
- . **Hioki M, Ikeshita M, Iedokoro Y, et al.** Successful combined operation for mitral stenosis and atrial fibrillation. *Ann Thorac Surg* 1993;55:776-778.
- . **Hirsh J, Warkentin TE, Shaughnessy SG, et al.** Heparin and lowmolecular- weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. *Chest* 2001;119:64S–94S.
- . **Howitt A, Armstrong D.** Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. *BMJ* 1999;318:1324 –7.
- . **Hsu LF, Jais P, Keane D, et al.** Atrial fibrillation originating from persistent left superior vena cava. *Circulation*. 2004; 109: 828–32.

References

- . **Hurlen M, Abdelnoor M, Smith P, et al.** Warfarin, aspirin, or both after myocardial infarction. *N Engl J Med* 2002;347:969–74.
- . **Hylek EM, Go AS, Chang Y, et al.** Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. *N Engl J Med* 2003;349:1019–26.
- . **Hylek EM, Singer DE.** Risk factors for intracranial hemorrhage in outpatients taking warfarin. *Ann Intern Med* 1994;120:897–902.
- . **Jais P, Haissaguerre M, Shah DC, et al.** A focal source of atrial fibrillation treated by discrete radiofrequency ablation. *Circulation*. 1997; 95: 572–6.
- . **Julian DG, Camm AJ, Frangin G, et al.** Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: **EMIAT** European Myocardial Infarct Amiodarone Trial Investigators. *Lancet* 1997;349:667-674. [Errata, *Lancet* 1997;349:1180, 1776.]
- . **Kanter MC, Tegeler CH, Pearce LA, et al.** Carotid stenosis in patients with atrial fibrillation. Prevalence, risk factors, and relationship to stroke in the Stroke Prevention in Atrial Fibrillation Study. *Arch Intern Med*. 1994; 154: 1372–7.
- . **Karch, MR, Zrenner, B, Deisenhofer, I, et al.** Freedom from atrial tachyarrhythmias after catheter ablation of atrial fibrillation: a randomized comparison between 2 current ablation strategies. *Circulation* 2005;111,2875-2880
- . **Kay GN, Bubien RS, Epstein AE, et al.** Effect of catheter ablation of the atrioventricular junction on quality of life and exercise tolerance in paroxysmal atrial fibrillation. *Am J Cardiol* 1988;62:741-744.
- . **Kempster PA, Gerraty RP, Gates PC.** Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. *Stroke*. 1988; 19: 955–7.
- . **Kerr CR, Boone J, Connolly SJ, et al.** The Canadian Registry of Atrial Fibrillation: a noninterventional follow-up of patients after the first diagnosis of atrial fibrillation. *Am J Cardiol*. 1998; 82: 82N–5N.
- . **Khan IA.** *Atrial stunning*: determinants and cellular mechanisms. *Am Heart J*. 2003; 145: 787–94.

- . **Klein GJ, Bashore TM, Sellers TD, et al.** Ventricular fibrillation in the Wolff-Parkinson-White syndrome. *N Engl J Med.* 1979; 301: 1080–5.
- . **Knight BP, Gersh BJ, Carlson MD, et al.** Role of permanent pacing to prevent atrial fibrillation: science advisory from the American Heart Association Council on Clinical Cardiology (Subcommittee on Electrocardiography and Arrhythmias) and the quality of Care and Outcomes Research Interdisciplinary Working Group, in collaboration with the Heart Rhythm Society. *Circulation* 2005;111:240-243.
- . **Knight BP, Michaud GF, Strickberger SA, et al.** Electrocardiographic differentiation of atrial flutter from atrial fibrillation by physicians. *J Electrocardiol.* 1999; 32: 315–9.
- . **Kober L, Bloch Thomsen PE, Moller M, et al.** Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. *Lancet* 2000;356:2052-2058.
- . **Kowey PR, Stebbins D, Igidbashian L, et al.** Clinical outcome of patients who develop PAF after CABG surgery. *Pacing Clin Electrophysiol* 2001; 24:191-193.
- . **Krahn AD, Klein GJ, Kerr CR, et al.** How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators. *Arch Intern Med.* 1996; 156: 2221–4.
- . **Kubitza D, Becka M, Zuehlsdorf M, Mueck W.** Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. *J Clin Pharmacol.* 2007;47:218–26.
- . **Landefeld CS, Goldman L.** Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. *Am J Med* 1989;87:144 –52.
- . **Le Heuzey JY, Pazioud O, Piot O, et al.** Cost of care distribution in atrial fibrillation patients: the COCAF study. *Am Heart J.* 2004; 147: 121–6
- . **Lechat P, Lardoux H, Mallet A, et al.** Anticoagulant (fluindione)-aspirin combination in patients with high-risk atrial fibrillation. A randomized trial (Fluindione, Fibrillation Auriculaire, Aspirin et Contraste Spontane; FFAACS). *Cerebrovasc Dis* 2001;12:245–52.

References

- . **Lindeboom JE, Kingma JH, Crijns HJ, et al.** Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter. *Am J Cardiol* 2000;85:1031-1033.
- . **Lin LJ, Cheng MH, Lee CH, et al.** Compliance with antithrombotic prescribing guidelines for patients with atrial fibrillation--a nationwide descriptive study in Taiwan. *Clin Ther.* 2008 Sep;30(9):1726-36.
- . **Lip, GY, Karpha, M** .Anticoagulant and antiplatelet therapy use in patients with atrial fibrillation undergoing percutaneous coronary intervention: the need for consensus and a management guideline. *Chest* 2006;130,1823-1827.
- . **Lleva P, Aronow WS, Gutwein AH:** Prevalence of inappropriate use of digoxin in 136 patients on digoxin and prevalence of use of warfarin or aspirin in 89 patients with persistent or paroxysmal atrial fibrillation. *Am J Ther.* 2009 Nov-Dec; 16(6):e41-3.
- . **Lown B, Amarasingham R, Neuman J.** New method for terminating cardiac arrhythmias: use of synchronized capacitor discharge. *JAMA* 1962;182:548.
- . **Lown B, Krieger R, Williams J.** Cardioversion and digitalis drugs: changed threshold to electrical shock in digitalized animals. *Circ Res* 1965;17:519-531.
- . **Madrid AH, Bueno MG, Rebollo JM, et al.** Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. *Circulation* 2002;106:331-336.
- . **Madrid AH, Moro C, Marin-Huerta E, et al.** Comparison of flecainide and procainamide in cardioversion of atrial fibrillation. *Eur Heart J* 1993;14:1127-1131.
- . **Maggioni AP, Latini R, Carson PE, et al.** Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). *Am Heart J.* 2005; 149: 548–57.
- . **Maisel WH.** Autonomic modulation preceding the onset of atrial fibrillation. *J Am Coll Cardiol.* 2003; 42: 1269–70.

- . **Mandapati R, Skanes A, Chen J, Berenfeld O, Jalife J.** Stable microreentrant sources as a mechanism of atrial fibrillation in the isolated sheep heart. *Circulation*. 2000; 101: 194–99.
- . **Manning WJ, Silverman DI, Katz SE, et al.** Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. *J Am Coll Cardiol*. 1994; 23: 1535–40.
- . **Manning WJ, Silverman DI, Keighley CS, et al.** Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. *J Am Coll Cardiol*. 1995; 25: 1354–61.
- . **Mant, J, Hobbs, FDR, Fletcher, K, et al** .Warfarin versus aspirin for stroke prevention in atrial fibrillation in the elderly community population: the Birmingham Atrial Fibrillation Treatment of the Aged Study (BAFTA), a randomised controlled trial. *Lancet* 2007;370,493-503
- . **MERIT-HF Study Group.** Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet*. 1999; 353: 2001–7.
- . **Miller VT, Rothrock JF, Pearce LA, et al.** Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. *Neurology*. 1993; 43: 32–6.
- . **Mittal S, Ayati S, Stein KM, et al.** Transthoracic cardioversion of atrial fibrillation: comparison of rectilinear biphasic versus damped sine wave monophasic shocks. *Circulation* 2000;101:1282-1287.
- . **Moe GK, Abildskov JA.** Atrial fibrillation as a self sustaining arrhythmia independent of focal discharge. *Am Heart J*. 1959; 58: 59–70.
- . **Morocutti C, Amabile G, Fattapposta F, et al.** Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators. *Stroke*. 1997; 28: 1015–21.
- . **Moulton AW, Singer DE, Haas JS.** Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. *Am J Med* 1991;91:156–61.

- . **Mueck W, Borris LC, Dahl OE, et al.** Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. *Thromb Haemost.* 2008;100:453–61.
- . **Mugge A, Kuhn H, Nikutta P, et al.** Assessment of left atrial appendage function by biplane transesophageal echocardiography in patients with nonrheumatic atrial fibrillation: identification of a subgroup of patients at increased embolic risk. *J Am Coll Cardiol.* 1994; 23: 599–607.
- . **Murray RD, Deitcher SR, Shah A, et al.** Potential clinical efficacy and cost benefit of a transesophageal echocardiography-guided low-molecular-weight heparin (enoxaparin) approach to antithrombotic therapy in patients undergoing immediate cardioversion from atrial fibrillation. *J Am Soc Echocardiogr.* 2001; 14: 200–8.
- . **Nademanee K, McKenzie J, Kosar E, et al.** A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. *J Am Coll Cardiol* 2004;43:2044-2053.
- . **Nakao K, Seto S, Ueyama C, et al.** Extended distribution of prolonged and fractionated right atrial electrograms predicts development of chronic atrial fibrillation in patients with idiopathic paroxysmal atrial fibrillation. *J Cardiovasc Electrophysiol.* 2002; 13: 996–1002.
- . **Nattel S.** New ideas about atrial fibrillation 50 years on. *Nature.* 2002; 415: 219–26.
- . **Nieuwlaat R, Barker L, Kim YK, et al.** Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. *Thromb Res.* 2009 Nov 20. Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
- . **Ninios I, Bogossian H, Zarse M, et al.** Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: insights from the first prospective population-based study in rural Greece. *-J Thromb Thrombolysis.* 2009 Nov 17.
- . **Odén A, Fahlén M, Hart RG.** Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. *Thromb Res* 2006;117: 493–9.

References

- . **Olsson SB**. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. *Lancet* 2003; 362:1691–8.
- . **Omran, H, Jung, W, Rabahieh, R, et al**. Left atrial appendage function in patients with atrial flutter. *Heart* 1997;78,250-254.
- . **Opolski G, Torbicki A, Kosior DA, et al**, for the Investigators of the Polish HOT CAFE Trial. *Chest* 2004;126:476-486.
- . **Ostermayer SH, Reisman M, Kramer PH, et al**. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. *J Am Coll Cardiol* 2005;
- . **Packer DL, Bardy GH, Worley SJ, et al**. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. *Am J Cardiol*. 1986; 57: 563–70.
- . **Padanilam BJ, Prystowsky EN**: Atrial fibrillation should ablation be first-line therapy and for whom: antagonist position. *Circulation* 2005;112(8): 1223-1229.
- . **Page RL, Wharton JM, Prystowsky EN**. Effect of continuous vagal enhancement on concealed conduction and refractoriness within the atrioventricular node. *Am J Cardiol*. 1996; 77: 260–5.
- . **Pappone C, Santinelli V, Manguso F, et al**. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. *Circulation*. 2004; 109: 327–34.
- . **Pearson AC, Labovitz AJ, Tatineni S, et al**. Superiority of transesophageal echocardiography in detecting cardiac source of embolism in patients with cerebral ischemia of uncertain etiology. *J Am Coll Cardiol*. 1991; 17: 66–72.
- . **Pedersen OD, Bagger H, Kober L, et al**. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. *Circulation*. 1999; 100: 376–80.

References

- . **Pelargonio G, Prystowsky EN**: Rate versus rhythm control in the management of patients with atrial fibrillation. *Nat Clin Pract* 2005;2(10):514-521.
- . **Perez-Gomez F, Alegria E, Berjon J, et al.** Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. *J Am Coll Cardiol*. 2004; 44: 1557–66.
- . **Petersen P, Hansen JM**. Stroke in thyrotoxicosis with atrial fibrillation. *Stroke* 1988;19:15– 8.
- . **Petersen P**. Thromboembolic complications in atrial fibrillation. *Stroke* 1990;21:4 –13.
- . **Pokharel S, van Geel PP, Sharma UC, et al.** Increased myocardial collagen content in transgenic rats overexpressing cardiac angiotensin-converting enzyme is related to enhanced breakdown of N-acetyl-Ser-Asp-Lys-Pro and increased phosphorylation of Smad2/3. *Circulation*. 2004; 110: 3129–35.
- . **Polontchouk L, Haefliger JA, Ebelt B, et al.** Effects of chronic atrial fibrillation on gap junction distribution in human and rat atria. *J Am Coll Cardiol*. 2001; 38: 883–91.
- . **Posada IS, Barriales V**. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. *Am Heart J*. 1999; 138: 137–43.
- . **Prystowsky EN, Benson DW, Fuster V, et al.** Management of patients with atrial fibrillation: a statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. *Circulation* 1996;93:1262-1277.
- . **Prystowsky EN, Freeland SA, Branyas NA, et al.** Clinical experience with dofetilide in the treatment of patients with atrial fibrillation. *J Cardiovasc Electrophysiol* 2003;14:S287-S290.
- . **Prystowsky EN, Katz AM**. Atrial fibrillation. In: *Textbook of Cardiovascular Medicine*. Philadelphia: Lippincott-Raven, 1998: 1661.
- . **Prystowsky EN**. Management of atrial fibrillation: therapeutic options and clinical decisions. *Am J Cardiol* 2000;85:3D-11D.

- . **Prystowsky EN**. Proarrhythmia during drug treatment of supraventricular tachycardia: paradoxical risk of sinus rhythm for sudden death. *Am J Cardiol* 1996;78(8A):35-41.
- . **Prystowsky EN**. Tachycardia-induced-tachycardia: a mechanism of initiation of atrial fibrillation. In: DiMarco JP, Prystowsky EN, editors. *Atrial Arrhythmias: State of the Art*. Armonk, NY: Futura, 1995.
- . **Psaty BM, Manolio TA, Kuller LH, et al**. Incidence of and risk factors for atrial fibrillation in older adults. *Circulation*. 1997; 96: 2455–61.
- . **Putnam W, Nicol K, Anderson D, et al**. Anticoagulation in atrial fibrillation. Is there a gap in care for ambulatory patients? Dalhousie University, Department of Family Medicine, Dalhousie University, Halifax, NS.
- . **Ricard P, Levy S, Trigano J, et al**. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. *Am J Cardiol*. 1997; 79: 815–6.
- . **Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation**. Analysis of pooled data from five randomized controlled trials [published erratum appears in *Arch Intern Med* 1994;154:2254]. *Arch Intern Med*. 1994; 154: 1449–57
- . **Robinson K, Frenneaux MP, Stockins B, et al**. Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. *J Am Coll Cardiol* 1990;15:1279–85.
- . **Roden DM**. Ibutilide and the treatment of atrial arrhythmias. *Circulation* 1996;94:1499-1502.
- . **Rothberg, MB, Celestin, C, Fiore, LD, et al** Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: metaanalysis with estimates of risk and benefit. *Ann Intern Med* 2005;143,241-250.
- . **Roy D, Talajic M, Dorian P, et al**. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. *N Engl J Med* 2000;342:913-920.
- . **SALAH ATTA, SHIRIN ABDEL-SALAM, YEHIA KISHK**: Current Care Gap of Proper Anticoagulation in Patients with Atrial Fibrillation Patients of Upper Egypt, *Egypt Heart* 2007; J 59 (3): 301-306.

References

- . **Salerno DM, Dias VC, Kleiger RE, et al.** Efficacy and safety of intravenous diltiazem for treatment of atrial fibrillation and atrial flutter: the Diltiazem-Atrial Fibrillation/Flutter Study Group. *Am J Cardiol* 1989;63:1046-1051.
- . **Sanders P, Berenfeld O, Hocini M, et al.** Spectral analysis identifies sites of high-frequency activity maintaining atrial fibrillation in humans. *Circulation*. 2005; 112: 789–97.
- . **Sanders P, Morton JB, Davidson NC, et al.** Electrical remodeling of the atria in congestive heart failure: electrophysiological and electroanatomic mapping in humans. *Circulation*. 2003; 108: 1461–8.
- . **Sanfilippo AJ, Abascal VM, Sheehan M, et al.** Atrial enlargement as a consequence of atrial fibrillation. A prospective echocardiographic study. *Circulation*. 1990; 82: 792–7.
- . **Sata N, Hamada N, Horinouchi T, et al.** C-reactive protein and atrial fibrillation. Is inflammation a consequence or a cause of atrial fibrillation? *Jpn Heart J*. 2004; 45: 441–5.
- . **Savelieva I, Camm AJ.** Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. *J Interv Card Electrophysiol*. 2000; 4: 369–82.
- . **Seto, TB, Buchholz, WA, Douglas, PS, et al.** When the body and appendage of the left atrium disagree: “focal” atrial fibrillation; implications for atrial thrombus formation and risk of thromboembolism. *J Am Soc Echocardiogr* 1999;12,1097-1100
- . **Seidl, K, Rameken, M, Drogemuller, A, et al.** Embolic events in patients with atrial fibrillation and effective anticoagulation: value of transesophageal echocardiography to guide direct-current cardioversion: final results of the Ludwigshafen Observational Cardioversion Study. *J Am Coll Cardiol* 2002;39,1436-1442
- . **Scheinman MM, Morady F, Hess DS, et al.** Catheter induced ablation of the atrioventricular junction to control refractory supraventricular arrhythmias. *JAMA* 1982;248:851-855.
- . **Schwartzman D, Bazaz R, Nosbisch J.** Common left pulmonary vein: a consistent source of arrhythmogenic atrial ectopy. *J Cardiovasc Electrophysiol*. 2004; 15: 560–6.

References

- . **Shah D, Haissaguerre M, Jais P, et al.** Nonpulmonary vein foci: do they exist? *Pacing Clin Electrophysiol.* 2003; 26: 1631–5.
- . **Shapiro, EP, Effron, MB, Lima, S** .Transient atrial dysfunction after conversion of chronic atrial fibrillation to sinus rhythm. *Am J Cardiol* 1988;62,1202-1207
- . **Shigematsu Y, Hamada M, Mukai M, et al.** Mechanism of atrial fibrillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. *Jpn Circ J* 1995;59:329 –36.
- . **Shinbane JS, Wood MA, Jensen DN, et al.** Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. *J Am Coll Cardiol.* 1997; 29: 709–15.
- . **Shireman TI, Howard PA, Kresowik TF, et al.** Combined anticoagulant antiplatelet use and major bleeding events in elderly atrial fibrillation patients. *Stroke* 2004;35:2362–7.
- . **Singer DE, Albers GW, Dalen JE, et al.** Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). *Chest* 2008;133:Suppl:546S-592S.
- . **Singh BN, Singh SN, Reda DJ, et al.** Amiodarone versus sotalol for atrial fibrillation. *N Engl J Med.* 2005; 352: 1861–72.
- . **Sparks PB, Jayaprakash S, Vohra JK, et al.** Left atrial "stunning" following radiofrequency catheter ablation of chronic atrial flutter. *J Am Coll Cardiol.* 1998; 32: 468–75.
- . **SPIRIT** Trial European Atrial Fibrillation Trial (EAFT) study groups. *Neurology* 1999;53:1319 –27.
- . **Stein PD, Alpert JS, Bussey HI, et al.** Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. *Chest* 2001;119: 220S–7S.
- . **Stellbrink C, Nixdorff U, Hofmann T, et al.** Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. *Circulation* 2004;109:997–1003.

References

- . **Stewart S, Hart CL, Hole DJ, et al.** A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. *Am J Med.* 2002; 113: 359–64.
- . **Stoddard MF, Dawkins PR, Prince CR, et al.** Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. *J Am Coll Cardiol.* 1995; 25: 452–9.
- . **Stollberger C, Chnupa P, Kronik G, et al.** Transesophageal echocardiography to assess embolic risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. *Ann Intern Med.* 1998; 128: 630–8.
- . **Stroke Prevention in Atrial Fibrillation Investigators.** Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation Study. *J Stroke Cerebrovasc Dis.* 1995; 5: 147–57.
- . **Stroke Prevention in Atrial Fibrillation Investigators.** Stroke Prevention in Atrial Fibrillation Study. Final results. *Circulation.* 1991; 84: 527–39.
- . **Stroke Prevention in Atrial Fibrillation Investigators:** a differential effect of aspirin in the Stroke Prevention in Atrial Fibrillation study. *J Stroke Cerebrovasc Dis.* 1993; 3: 181–8.
- . **Stroke Prevention on Atrial Fibrillation Investigators.** Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. *Lancet.* 1996; 348: 633–8.
- . **Stroke prevention in patients with nonvalvular atrial fibrillation:** a randomized trial. *JAMA* 2005;293:690–8.
- . **Sung RJ, Tan HL, Karagounis L, et al.** Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. The Sotalol Multicenter Study Group. *Am Heart J* 1995;129:739-748.
- . **The CONSENSUS Trial Study Group.** Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). *N Engl J Med.* 1987; 316: 1429–35.

- . ***The SOLVD Investigators.*** Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. *N Engl J Med.* 1992; 327: 685–91.
- . ***The SOLVD Investigators.*** Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. *N Engl J Med.* 1991; 325: 293–302.
- . ***The SPAF III- Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin:*** Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. *JAMA* 1998;279:1273–7.
- . ***The Stroke Prevention in Atrial Fibrillation Investigators.*** Bleeding during antithrombotic therapy in patients with atrial fibrillation. *Arch Intern Med.* 1996; 156: 409–16.
- . ***Toff WD, Camm AJ, Skehan JD.*** United Kingdom Pacing and Cardiovascular Events Trial Investigators. Single-chamber versus dual-chamber pacing for high-grade atrioventricular block (UKPACE). *N Engl J Med* 2005; 353:145-155.
- . ***Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al.*** Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. *N Engl J Med* 1999;341:857-865.
- . ***Tsai LM, Chen JH, Lin LJ, et al.*** Natural history of left atrial spontaneous echo contrast in nonrheumatic atrial fibrillation. *Am J Cardiol.* 1997; 80: 897–900.
- . ***Tsivgoulis G, Spengos K, Zakopoulos N, et al.*** Efficacy of anticoagulation for secondary stroke prevention in older people with non-valvular atrial fibrillation: a prospective case series study. *Age Ageing* 2005;34: 35–40.
- . ***Turpie AG, Gent M, Laupacis A, et al.*** A comparison of aspirin with placebo in patients treated with warfarin after heart-valve replacement. *N Engl J Med.* 1993; 329: 524–9.
- . ***Van Den Berg MP, Crijns HJ, Haaksma J, et al.*** Analysis of vagal effects on ventricular rhythm in patients with atrial fibrillation. *Clin Sci (Colch).* 1994; 86: 531–5.

- . **Van Den Berg MP, Tuinenburg AE, van Veldhuisen DJ, et al.** Cardioversion of atrial fibrillation in the setting of mild to moderate heart failure. *Int J Cardiol.* 1998; 63: 63–70.
- . **Van Es RF, Jonker JJ, Verheugt FW, et al.** Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. *Lancet* 2002;360:109 –13.
- . **Van Walraven C, Hart RG, Wells GA, et al.** A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. *Arch Intern Med* 2003;163:936–43.
- . **Verheule S, Wilson E, Everett T, et al.** Alterations in atrial electrophysiology and tissue structure in a canine model of chronic atrial dilatation due to mitral regurgitation. *Circulation.* 2003; 107: 2615–22.
- . **Vita JA, Friedman PL, Cantillon C, et al.** Efficacy of intravenous propafenone for the acute management of atrial fibrillation. *Am J Cardiol* 1989; 63:1275-1278.
- . **Volgman AS, Carberry PA, Stambler B, et al.** Conversion efficacy and safety of intravenous ibutilide compared with intravenous procainamide in patients with atrial flutter or fibrillation. *J Am Coll Cardiol* 1998;31:1414-1419.
- . **Wachtell K, Lehto M, Gerds E, et al.** Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. *J Am Coll Cardiol* 2005;45:712-719.
- . **Wang TJ, Larson MG, Levy D, et al.** Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. *Circulation.* 2003; 107: 2920–5.
- . **Wang TJ, Massaro JM, Levy D, et al.** A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA* 2003;290:1049 –56.
- . **Wang TJ, Parise H, Levy D, et al.** Obesity and the risk of new-onset atrial fibrillation. *JAMA.* 2004; 292: 2471–7.

References

- . **Warkentin TE, Levine MN, Hirsh J, et al.** Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. *N Engl J Med* 1995;332:1330–5.
- . **Wijffels MC, Kirchhof CJ, Dorland R, et al.** Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. *Circulation*. 1995; 92: 1954–68.
- . **Wolf PA, Abbott RD, Kannel WB.** Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991; 22: 983–8.
- . **Wolf PA, Dawber TR, Thomas HE Jr, et al.** Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. *Neurology*. 1978; 28: 973–7.
- . **Yamada T, Fukunami M, Shimonagata T, et al.** Prediction of paroxysmal atrial fibrillation in patients with congestive heart failure: a prospective study. *J Am Coll Cardiol*. 2000; 35: 405–13.
- . **Yang Y, Grosset DG, Li Q, et al.** Identification of echocardiographic "smoke" in a bench model with transcranial Doppler ultrasound. *Stroke*. 2000; 31: 907–14.
- . **Yang Y, Xia M, Jin Q, et al.** Identification of a KCNE2 gain-of-function mutation in patients with familial atrial fibrillation. *Am J Hum Genet*. 2004; 75: 899–905.
- . **Yoshida M, Nakamura Y, Higashikawa M, et al.** Predictors of ischemic stroke in non-rheumatic atrial fibrillation. *Int J Cardiol*. 1996; 56: 61–70.
- . **Zabalgoitia M, Halperin JL, Pearce LA, et al.** Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. *J Am Coll Cardiol*. 1998; 31: 1622–6.